A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs RXI 109 (Primary)
- Indications Hypertrophic scars
- Focus Therapeutic Use
- Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals
- 13 Jun 2016 Status changed from active, no longer recruiting to completed.
- 25 Mar 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 23 Mar 2015 Preliminary results published in the Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History